In search of definitions: Cancer‐associated fibroblasts and their markers
By M. Nurmik, P. Ullmann, F. Rodriguez, S. Haan, E. Letellier. International Journal of Cancer, 2019
602 citations recorded by the source corpus.
The tumor microenvironment has been identified as one of the driving factors of tumor progression and invasion. Inside this microenvironment, cancer‐associated fibroblasts (CAFs), a type of perpetually activated fibroblasts, have been implicated to have a strong tumor‐modulating effect and play a key role in areas such as drug resistance. Identification of CAFs has typically been carried based on the expression of various “CAF markers”, such as fibroblast activation protein alpha (FAP) and alpha smooth muscle actin (αSMA), which separates them from the larger pool of fibroblasts present in the body. However, as outlined in this Review, the expression of various commonly used fibroblast markers is extremely heterogeneous and varies strongly between different CAF subpopulations. As such, novel selection methods based on cellular function, as well as further characterizing research, are vital for the standardization of CAF identification in order to improve the cross‐applicability of different research studies in the field. The aim of this review is to give a thorough overview of the commonly used fibroblast markers in the field and their various strengths and, more importantly, their weaknesses, as well as to highlight potential future avenues for CAF identification and targeting.
Subfields: Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/25e99abef8c2f1eb1d362ac49a19095985a4737b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- K. Seidi
- Qingcai Meng
- Roghayyeh Baghban
- Rana Jahanban-Esfahlan
- M. Jaymand
- Xianjun Yu
- Jin Xu
- Chen Liang
Citations in the corpus
- Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives (2021, background): “for potential clinical application, FAP has been prominent in recent studies of CAF-targeted therapy [324, 325].”
- Tumor microenvironment complexity and therapeutic implications at a glance (2020, background): “CAFs residing in TME are heterogeneous cells with different origins, different functions (pro or anti-tumor activities) and different surface markers such as alpha-smooth muscle actin (α-SMA), myosin light chain 9 (MYL9), myosin light chain kinase (MYLK), matrix metalloproteinase 2 (MMP2), decorin (”